Suchergebnisse - "Cook, Gordon"

PubPharm (20)

1

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma : results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

enthalten in: British journal of haematology | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

2

The MUK eight protocol : a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

enthalten in: Trials | 2020

von Hinsley, S. | Walker, K. | Sherratt, D. | +13

3

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

enthalten in: Blood | 2020

von Craig, Z. | Cook, G. | Pawlyn, C. | +13

CommentIn: Blood. 2020 Aug 27;136(9):1019-1021. - PMID 32853375

4

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : extended follow-up of POLLUX, a randomized, open-label, phase 3 study

enthalten in: Leukemia | 2020

von Bahlis, N. | Dimopoulos, M. | White, D. | +16

5

Clonal evolution in myeloma : the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients

enthalten in: Haematologica | 2019

von Jones, J. | Weinhold, N. | Ashby, C. | +20

CommentIn: Haematologica. 2019 Jul;104(7):1292-1293. - PMID 31257204

6

Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)

enthalten in: British journal of haematology | 2019

von Popat, R. | Brown, S. | Flanagan, L. | +10

7

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma : findings of the Medical Research Council Myeloma IX randomised study

enthalten in: British journal of haematology | 2018

von Royle, K. | Gregory, W. | Cairns, D. | +8

8

Neutral tumor evolution in myeloma is associated with poor prognosis

enthalten in: Blood | 2017

von Johnson, D. | Lenive, O. | Mitchell, J. | +14

9

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone : A pooled analysis

enthalten in: European journal of haematology | 2017

von Moreau, P. | Dimopoulos, M. | Richardson, P. | +24

10

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six) : a multicentre, open-label, phase 1/2 trial

enthalten in: The Lancet. Haematology | 2016

von Popat, R. | Brown, S. | Flanagan, L. | +10

CommentIn: Lancet Haematol. 2016 Dec;3(12):e552-e553. - PMID 27843121